Tiragolumab (anti-TIGIT)

製品コード：A2028         Batch: A202805

印刷

Tiragolumab (anti-TIGIT) (RG6058, MTIG7192A) is a humanized IgG1/kappa monoclonal antibody that binds TIGIT to prevent its interaction with its ligand PVR (CD155).

製品説明

CAS No. 1918185-84-8
Isotype Human IgG1, κ
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 12.27mg/ml
Endotoxin Level ＜1EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Combined dendritic cell and anti-TIGIT immunotherapy potentiates adaptive NK cells against HIV-1 [ EMBO Mol Med, 2025, 10.1038/s44321-025-00255-x] PubMed: 40473838
Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy [ NPJ Precis Oncol, 2025, 9(1):142] PubMed: 40374899
Novel insights into immune checkpoints in HIV/SHIV infection: from SHIVSF162P3-infected elite controllers to therapeutic strategy [ J Virol, 2025, 99(8):e0078525] PubMed: 40637373
Dual targeting of CD155/TIGIT and PD-L1/PD-1 immune checkpoints potentiates NK cell-mediated cytotoxicity in medulloblastoma [ Neurooncol Adv, 2025, 7(1):vdaf099] PubMed: 40703802
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer [ Cancer Cell, 2024, 42(12):2045-2063.e10] PubMed: 39658541
Inhibition of Cbl-b restores effector functions of human intratumoral NK cells [ J Immunother Cancer, 2024, 12(11)e009860] PubMed: 39551607
The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling [ Cell Commun Signal, 2024, 22(1):35] PubMed: 38216949
Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer [ bioRxiv, 2024, 2024.03.19.585657] PubMed: 38562799
Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies [ J Immunother Cancer, 2023, 11(12)e007502] PubMed: 38081778

人間や獣医の診断であるか治療的な使用のためにでない。